Idenix Pharmaceuticals LLC

Idenix Pharmaceuticals LLC has been granted 38 US utility patents between 2015 and 2021, placing Idenix Pharmaceuticals LLC at rank #8,411 across all assignees tracked by PlainPatent. This portfolio spans 14 distinct Cooperative Patent Classification (CPC) subclasses, averaging 25.6 claims per patent with primary concentration in A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS). As a US Corporation, Idenix Pharmaceuticals LLC is one of the more focused assignees in the PatentsView dataset. The composite Innovation Score of 40.9/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 11 grants, compared with 27 in the 2015–2019 window — a -59% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. Idenix Pharmaceuticals LLC's 25.6 average claims per patent reflects complex, broadly scoped inventions that are difficult for competitors to design around, while concentration in 14 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Idenix Pharmaceuticals LLC against peers pursuing similar technology classes.